Xenetic Biosciences, Inc. (XBIO): auditor change — Xenetic Biosciences' auditor Marcum resigns due to acquisition; CBIZ engaged as new auditor

Xenetic Biosciences, Inc.

Marcum resigned as auditor on April 8, 2025, after CBIZ acquired its attest business; Audit Committee approved.
No disagreements or reportable events between company and Marcum during FY2024, FY2023, and through resignation.
CBIZ engaged as new independent auditor on April 9, 2025, for the fiscal year ending December 31, 2025.
Marcum's audit reports for FY2024 and FY2023 were unqualified, with no adverse opinion or modifications.
No prior consultations with CBIZ on accounting or auditing matters.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Xenetic Biosciences, Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On April 9, 2025, with the approval of the Company’s Audit Committee, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Marcum LLP resigned as auditor of Xenetic Biosciences, Inc..

Action: resignation
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On April 8, 2025, Xenetic Biosciences, Inc. (the "Company") was notified by Marcum that Marcum resigned as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s Audit Committee approved the resignation.

View on SEC.gov

12 auditor changes filed in the last 30 days. Browse all auditor changes →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-002396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.